Cancer Archives

News and Trends 18 May 2015

Baxter’s spinoff Baxalta is building up its Oncology portfolio

Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important acquisition, Baxter is reinforcing its oncology presence by owning Oncaspar, a treatment against acute lymphocytic leukemia. Oncaspar is the only FDA-approved pegylated formulation of L-asparaginase, the enzyme that depletes the aminoacid asparagine. Whilst normal cells can produce asparagine, leukemic cells […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 May 2015

European companies present their cancer treatment solutions in the USA

Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC). Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. The British company that aims to provide low-priced and more diversed therapeutics, has developed ‘Site-Seeker’, a next-generation phenotypic screening platform based on PhoreMost’s Protein […]

May 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 30 Apr 2015

A new Microfluidic Chip technology raised €1.9Million

Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round was led by Redalpine Venture Partners in Zurich with the participation of private investors from Switzerland and the United Kingdom. Lunaphore’s young team wants to use this cash to develop its first tissue diagnostics platform. The young Swiss medtech company, […]

April 30, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 28 Apr 2015

PEP-Therapy Raised €1.3 Million in Seed Capital

France-based PEP-Therapy has raised €1.3M in initial funding. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable the cancer-focused company to undertake regulatory development of its first therapeutic product, a biomarker. The biomarker works as a predictive for foreseeing the effectiveness of a cancer treatment. The […]

April 28, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 23 Apr 2015

Are personalized treatments for lung cancer underutilized?

Results from a new global survey of lung cancer oncologists have shown that, despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for Epidermal Growth Factor Receptor mutations (EGFR), a significant number of those tested were not receiving personalized treatments for their cancer type and mutation subtype. The survey, with […]

April 23, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

OncoBEAM blood test arrives to Europe

Sysmex Inostics have signed an exclusive distributor agreement with IndivuTest, and its parent company Indivumed, a cancer research company focused on the development of individualized cancer diagnostics and therapies. This collaboration will offer Sysmex’s OncoBEAM services throughout Germany, Austria and Switzerland. IndivuTest will be responsible for commercial and sample logistics, with all testing being performed […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Erytech Strengthens its Intellectual Property Position in the US

Erytech strengthed its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent. The French biopharmaceutical company develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. The patent entitled “Medicament for […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Apr 2015

Another Partnership between Immunocore and MedImmune against Skin Cancer

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca have just entered into a second effective collaboration for a potential skin cancer treatment. It concerns melanoma which is a form of skin cancer that accounts for less than five per cent of […]

April 18, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 17 Apr 2015

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

Merck Serono appointed Dr. Alise Reicin as Senior Vice President, Head of Global Clinical Development. The appointment is yet another example of Merck’s clear interest in oncology and immunology, two fields in which Dr. Reicin expertised. Dr. Reicin will also bring extensive research and early/late clinical development expertise to Merck Serono. In her role as […]

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Baxter’s spinoff Baxalta is building up its Oncology portfolio

European companies present their cancer treatment solutions in the USA

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Natural Killer therapies for Cancer: a Fast-Evolving field

A new Microfluidic Chip technology raised €1.9Million

PEP-Therapy Raised €1.3 Million in Seed Capital

Are personalized treatments for lung cancer underutilized?

OncoBEAM blood test arrives to Europe

Erytech Strengthens its Intellectual Property Position in the US

Another Partnership between Immunocore and MedImmune against Skin Cancer

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!